% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jordan:300752,
      author       = {M. Jordan$^*$ and J. Morschl$^*$ and S. Autenrieth$^*$},
      title        = {{D}endritic cells in multiple myeloma: from immune evasion
                      to therapeutic potential.},
      journal      = {Frontiers in immunology},
      volume       = {16},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2025-00912},
      pages        = {1575509},
      year         = {2025},
      note         = {#EA:D431#LA:D431#},
      abstract     = {Multiple myeloma (MM) is a type of hematologic cancer
                      characterized by the uncontrolled clonal expansion of plasma
                      cells in the bone marrow (BM). This leads to significant
                      dysfunction and suppression of the immune system in affected
                      patients. Myeloma cells employ sophisticated strategies to
                      manipulate immune and non-immune cells, evading immune
                      surveillance and enhancing their survival. One key factor in
                      this evasion is the disruption of dendritic cell
                      (DC)-mediated immune mechanisms. Extensive evidence
                      indicates that in the presence of myeloma cells, DC numbers
                      are notably reduced, and their phenotype and function are
                      altered, impairing their ability to present antigens and
                      activate robust T-cell responses effectively. Despite rapid
                      advances in MM treatment, with promising strategies such as
                      DC-based vaccines being already achieved, DC dysfunction
                      remains a substantial hurdle, associated with or
                      contributing to poor therapeutic outcomes, disease relapse,
                      and MM's persistence as an incurable disease. To address
                      these challenges, it is essential to understand the
                      intricate mechanisms through which myeloma cells transform
                      DCs into their 'accomplices,' undermining immune responses.
                      This review comprehensively summarizes the current
                      understanding of the role of DCs in MM. Additionally, it
                      evaluates the potential of DCs in anti-MM immunotherapy,
                      discussing persistent challenges and highlighting emerging
                      perspectives that may lead to promising breakthroughs for
                      improved patient outcomes.},
      subtyp        = {Review Article},
      keywords     = {DC vaccine therapy (Other) / dendritic cells (Other) /
                      immune evasion (Other) / multiple myeloma (Other) / tumor
                      microenvironment (Other)},
      cin          = {D431},
      ddc          = {610},
      cid          = {I:(DE-He78)D431-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40313957},
      pmc          = {pmc:PMC12043573},
      doi          = {10.3389/fimmu.2025.1575509},
      url          = {https://inrepo02.dkfz.de/record/300752},
}